Hyppigheden af tilbagefald i den 6- måneders dobbeltblinde follow- up periode var henholdsvis 17% for duloxetin og 29% for placebo.
The incidence of relapse during the 6-months double-blind follow-up period was 17% and 29% for duloxetine and placebo, respectively.